About the Authors
- Vasanthy Vigneswara
-
Affiliations Neurotrauma and Neurodegeneration Section, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom, Neuregenix Ltd, The Science Park, Edgbaston, Birmingham, United Kingdom
- Martin Berry
-
Affiliations Neurotrauma and Neurodegeneration Section, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom, Neuregenix Ltd, The Science Park, Edgbaston, Birmingham, United Kingdom
- Ann Logan
-
Contributed equally to this work with: Ann Logan, Zubair Ahmed
Affiliations Neurotrauma and Neurodegeneration Section, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom, Neuregenix Ltd, The Science Park, Edgbaston, Birmingham, United Kingdom
- Zubair Ahmed
-
Contributed equally to this work with: Ann Logan, Zubair Ahmed
* E-mail: z.ahmed.1@bham.ac.uk
Affiliations Neurotrauma and Neurodegeneration Section, School of Clinical and Experimental Medicine, University of Birmingham, Birmingham, United Kingdom, Neuregenix Ltd, The Science Park, Edgbaston, Birmingham, United Kingdom
Competing Interests
This study was partly funded by grants from Neuregenix Ltd, with whom all authors have an affiliation to. Quark Pharmaceuticals Inc., Israel, provided the stable modified siCASP2 and Scr-siCASP2 used in this study. There are no further patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Author Contributions
Conceived and designed the experiments: MB AL ZA. Performed the experiments: VV MB ZA. Analyzed the data: VV ZA. Contributed reagents/materials/analysis tools: MB. Wrote the paper: VV MB AL ZA.